Protagonist Therapeutics PTGX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $74.06M-64.4% | $46.02M-89.4% | $209.22M-35.4% | $209.18M-34.5% | $207.8M-34.0% | ||
| $170.14M+21.3% | $159.29M+15.3% | $147.84M+11.9% | $143.8M+13.4% | $140.29M+10.9% | ||
| $46.39M+15.1% | $44.85M+3.2% | $42.37M-0.4% | $41.4M+3.3% | $40.29M+1.2% | ||
| $216.53M+19.9% | $204.14M+12.4% | $190.21M+8.9% | $185.2M+11.0% | $180.58M+8.6% | ||
| -$142.47M-623% | -$158.13M-163% | $19.01M— | $23.98M— | $27.22M— | ||
| -192.4%-205pp | -343.6%-402pp | 9.1%— | 11.5%— | 13.1%— | ||
| —— | —— | $182K— | $290K— | $351K— | ||
| -$115.38M-302% | -$129.31M-146% | $48.07M— | $53.78M— | $57.09M— | ||
| -$664K-174% | $838K-80.1% | $2.16M— | $1.74M— | $894K— | ||
| -$114.71M-304% | -$130.15M-147% | $45.91M— | $52.04M— | $56.19M— | ||
| -154.9%-182pp | -282.8%-346pp | 21.9%— | 24.9%— | 27%— | ||
| -$1.82-333% | -$2.06-149% | $0.65— | $0.73— | $0.78— | ||
| -$141.02M-603% | -$156.85M-162% | $20.03M— | $24.87M— | $28.05M— | ||
| -190.4%-204pp | -340.9%-399pp | 9.6%— | 11.9%— | 13.5%— | ||
| -$142.47M-623% | -$158.13M-163% | $19.01M— | $23.98M— | $27.22M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Protagonist Therapeutics's revenue?
- Protagonist Therapeutics (PTGX) generated $74.1M in revenue over the trailing twelve months, down 64.4% year over year.
- Is Protagonist Therapeutics profitable?
- Protagonist Therapeutics is not currently profitable: it reported a net loss of $114.7M over the trailing twelve months, a -154.9% net margin.
- What is Protagonist Therapeutics's earnings per share?
- Protagonist Therapeutics's diluted EPS over the trailing twelve months is $-1.82.
- Where does Protagonist Therapeutics's income statement data come from?
- Every line is extracted from Protagonist Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
